At Novartis Oncology, we are passionate about providing a broad range of new remedies and practical solutions that change the way patients live with cancer. Open Partnerships allow us to gain insights and build knowledge, driving clinical development based on scientific and patient insights. As part of our commitment to patients and health care professionals, we have developed Alliance sites with patient support materials, educational materials, clinical trial information and more.
- CML Alliance™
CML Alliance™ offers a wealth of resources designed to help you and your patients optimize Ph+ CML:
- Access monitoring
- Educational materials
- Patient support materials
- Clinical trial information, and more
When patients have Ph+ CML, you want to provide access to the full potential of advanced care for Ph+ CML— and now you can with CML Alliance.
- GIST Alliance™
GIST Alliance™ is a unique support program designed to help health care professionals optimize treatment outcomes in gastrointestinal stromal tumor (GIST) patients. GISTs are currently the most common mesenchymal tumors of the gastrointestinal tract, with an estimated 3,300 to 6,000 new cases reported each year in the United States.1,2 Approximately 2,500 of these cases are metastatic at diagnosis.3
- Iron Health Alliance™
The Iron Health Alliance™ is designed to increase awareness, provide support, and educate physicians and patients about iron toxicity. New research and diagnostic methods continue to drive clinical progress. These advancements translate into widespread patient benefits by enhancing education, improving access related to diagnostics, understanding adherence and encouraging higher standards of care.
- NET Alliance™
Neuroendocrine tumors, also known as NETs, are an uncommon type of cancer that is sometimes referred to as carcinoid. The NET Alliance™ is designed to help patients and caregivers better understand NETs and connect with one another to advance the knowledge and management of neuroendocrine tumors.